These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 31077910)
1. Current development of 5-nitrofuran-2-yl derivatives as antitubercular agents. Elsaman T; Mohamed MS; Mohamed MA Bioorg Chem; 2019 Jul; 88():102969. PubMed ID: 31077910 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of nitrofuranyl methyl N-heterocycles derivatives as novel antitubercular agents. Wang A; Li W; Wang B; Lv K; Wang H; Liu M; Guo H; Lu Y Future Med Chem; 2018 Sep; 10(17):2059-2068. PubMed ID: 29992836 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents. Wang A; Xu S; Chai Y; Xia G; Wang B; Lv K; Wang D; Qin X; Jiang B; Wu W; Liu M; Lu Y Bioorg Med Chem; 2022 Jan; 53():116529. PubMed ID: 34861474 [TBL] [Abstract][Full Text] [Related]
4. Conjugation of a 5-nitrofuran-2-oyl moiety to aminoalkylimidazoles produces non-toxic nitrofurans that are efficacious in vitro and in vivo against multidrug-resistant Mycobacterium tuberculosis. Krasavin M; Lukin A; Vedekhina T; Manicheva O; Dogonadze M; Vinogradova T; Zabolotnykh N; Rogacheva E; Kraeva L; Yablonsky P Eur J Med Chem; 2018 Sep; 157():1115-1126. PubMed ID: 30179748 [TBL] [Abstract][Full Text] [Related]
5. Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets. Dos Santos Fernandes GF; Jornada DH; de Souza PC; Chin CM; Pavan FR; Dos Santos JL Curr Med Chem; 2015; 22(27):3133-61. PubMed ID: 26282941 [TBL] [Abstract][Full Text] [Related]
6. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design. Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857 [TBL] [Abstract][Full Text] [Related]
7. [Recent progress in mycobacteriology]. Okada M; Kobayashi K Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602 [TBL] [Abstract][Full Text] [Related]
8. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Tomioka H Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755 [TBL] [Abstract][Full Text] [Related]
9. Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains. Onajole OK; Pieroni M; Tipparaju SK; Lun S; Stec J; Chen G; Gunosewoyo H; Guo H; Ammerman NC; Bishai WR; Kozikowski AP J Med Chem; 2013 May; 56(10):4093-103. PubMed ID: 23611124 [TBL] [Abstract][Full Text] [Related]
10. Recent developments of coumarin-containing derivatives and their anti-tubercular activity. Hu YQ; Xu Z; Zhang S; Wu X; Ding JW; Lv ZS; Feng LS Eur J Med Chem; 2017 Aug; 136():122-130. PubMed ID: 28494250 [TBL] [Abstract][Full Text] [Related]
11. Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent. Gallardo-Macias R; Kumar P; Jaskowski M; Richmann T; Shrestha R; Russo R; Singleton E; Zimmerman MD; Ho HP; Dartois V; Connell N; Alland D; Freundlich JS Bioorg Med Chem Lett; 2019 Feb; 29(4):601-606. PubMed ID: 30600207 [TBL] [Abstract][Full Text] [Related]
12. The Nitrofuran-Warhead-Equipped Spirocyclic Azetidines Show Excellent Activity against Komarova K; Vinogradova L; Lukin A; Zhuravlev M; Deniskin D; Chudinov M; Gureev M; Dogonadze M; Zabolotnykh N; Vinogradova T; Lavrova A; Yablonskiy P Molecules; 2024 Jun; 29(13):. PubMed ID: 38999023 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents. Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612 [TBL] [Abstract][Full Text] [Related]
14. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. Centers for Disease Control and Prevention (CDC) MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162 [TBL] [Abstract][Full Text] [Related]
15. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909 [TBL] [Abstract][Full Text] [Related]
16. Isoniazid derivatives and their anti-tubercular activity. Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957 [TBL] [Abstract][Full Text] [Related]
17. Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agents. Ran K; Gao C; Deng H; Lei Q; You X; Wang N; Shi Y; Liu Z; Wei W; Peng C; Xiong L; Xiao K; Yu L Bioorg Med Chem Lett; 2016 Aug; 26(15):3669-74. PubMed ID: 27289321 [TBL] [Abstract][Full Text] [Related]
18. Recent advances in the research of heterocyclic compounds as antitubercular agents. Yan M; Ma S ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656 [TBL] [Abstract][Full Text] [Related]
19. Attachment of a 5-nitrofuroyl moiety to spirocyclic piperidines produces non-toxic nitrofurans that are efficacious in vitro against multidrug-resistant Mycobacterium tuberculosis. Krasavin M; Lukin A; Vedekhina T; Manicheva O; Dogonadze M; Vinogradova T; Zabolotnykh N; Rogacheva E; Kraeva L; Sharoyko V; Tennikova TB; Dar'in D; Sokolovich E Eur J Med Chem; 2019 Mar; 166():125-135. PubMed ID: 30703656 [TBL] [Abstract][Full Text] [Related]
20. The potential of marine natural Products: Recent Advances in the discovery of Anti-Tuberculosis agents. Peng X; Zeng Z; Hassan S; Xue Y Bioorg Chem; 2024 Oct; 151():107699. PubMed ID: 39128242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]